GLP-NIT

Completed

Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity

Early Changes in Non-Invasive Hepatic and Metabolic Indices After Incretin-Based Therapy in Patients With Overweight or Obesity: Real-World Evidence From a Turkish Cohort

Lead sponsor

Goztepe Prof Dr Suleyman Yalcın City Hospital

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Actual enrollment

154

Study population

MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI 25-29.9

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07701005

Org study IDGLP-NIT

Timeline

Milestones

Study start2024-01-01actual

Primary completion2026-03-30actual

Study completion2026-04-15actual

Study first posted2026-07-14actual

Last update posted2026-07-15actual

Assets

Investigational agents

Semaglutide Tirzepatide

Who this study enrolls

MASH / NAFLD / liver fibrosisObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Adults with overweight or obesity at increased metabolic risk for MASLD, treated with subcutaneous semaglutide or tirzepatide for at least 12 weeks at a single tertiary-care internal medicine clinic in Turkey; both medications were self-funded (out-of-pocket), as they are not covered by the national health insurance system.

Inclusion criteria

•Adults aged 18 years or older

•Overweight (BMI 25.0-29.9 kg/m²) or obesity (BMI ≥30.0 kg/m²)

•Considered at increased metabolic risk for MASLD (overweight/obesity plus ≥1 additional cardiometabolic risk factor)

•Continuous treatment with subcutaneous semaglutide or tirzepatide for at least 12 weeks

Exclusion criteria

•Significant alcohol consumption (>30 g/day for men; >20 g/day for women)

•Chronic liver disease of other etiology (viral hepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease)

•Prior bariatric surgery

•Initiation or dose modification of pioglitazone, SGLT-2 inhibitors, or high-dose vitamin E within 3 months before baseline

•Concurrent use of known hepatotoxic agents (e.g., amiodarone, methotrexate)

•Missing clinical, anthropometric, or laboratory data at baseline or follow-up

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.